A federal judge ruled that CMS cannot make brand drug companies subtract the financial assistance they offer patients in the commercial market from the so-called best prices they must offer Medicaid. The ruling kills a Trump-era regulation that called for making drug companies ensure patients receive the entire benefit of financial assistance, and if they can’t, drug companies must subtract the value of those copay coupons from the prices they charge Medicaid. That financial assistance measure was supposed to take...